]> 2026-04-12T05:22:49-07:00 Rindopepimut (CDX-110) 0 en Primarily associated with injection site reactions and overall shows a favorable safety profile 2025-01-18T08:28:26Z 2460693.8530787 Rindopepimut (CDX-110) 0 [2,"smw-datavalue-wikipage-property-invalid-title","Has original text","A very different approach to developing a treatment vaccine, which has the virtue of\nbeing usable \"off-the-shelf\u201d, without modification for individual patients, targets a\nmutation of the epidermal growth factor receptor, known as variant III, which occurs in\n25-40% of GBMs. One reason that EGFR inhibitors such as Iressa have not been more\neffective is that they target the normal EGFR receptor, not this mutated receptor. EGFR\nvariant III is also rarely seen in anything other than GBM tumors. To be eligible for the\ntrial, patients must first be tested whether they possess the mutation.\n\nDisappointing news was delivered by Celldex in a press release dated March 7, 2016,\nwhen the company announced that the phase III ACT IV clinical trial of rindopepimut for\nnewly diagnosed glioblastoma patients with minimal disease would be discontinued, after\nan independent review board found that the trial was unlikely to meet its primary\nendpoint (improved overall survival). Although survival results were consistent with\nprevious phase II trials, the control arm in this trial had survival outcomes that were\nbetter than expected (median overall survival was 20.4 months in the rindopepimut arm\nand 21.1 months in the control arm, hazard ratio = 0.99).\n\nRindopepimut is also being tested in a randomized phase II trial for recurrent\nglioblastoma called ReACT, in combination with Avastin. Data presented at the ASCO\n2015 meeting showed that the primary endpoint of the trial (six month progression-free\nsurvival) was met. PFS-6 was 30% in the rindopepimut + Avastin arm, versus 12% in the\ncontrol arm (per protocol). Additional data (reference 340, abstract IMCT-08) was\npresented later in 2015 at the SNO meeting, where it was reported that overall survival\nwas also significantly improved and 2-year survival was 25% for the rindopepimut arm\nversus 0% in the control arm. Patients receiving rindopepimut had also reduced\ndependency on steroids, as 33% of patients were able to cease steroid treatment for six\nmonths or longer, versus none in the control group.\n\nWhile the development of Rintega (rindopepimut) as a first-line treatment for GBM is\n\nunlikely to continue given these trial results, the therapy still holds promise combined\nwith Avastin in the recurrent setting, according to the outcomes of the ReACT trial."] Rindopepimut (CDX-110)# ERRa3f62c6665776505f0db7c26c19aebf1 Has treatment name 102 en Has treatment name